Class summary at a glance.

Every drug in the Arteriolar Vasodilator class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $134.6Mcombined across class
Total Rx claims: 10.1M3.1M unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Hydralazine

Brand: Hydralazine · 9.1M Part D claims (CY24) · 2.7M beneficiaries · First FDA approval: 1990-09-30

17 generic mfrs 0 plans require PA Active FDA shortage

Low NADAC$0.027

→

Avg plan cost$0.043

Part D spend $119.9M 2× spread, current vs floor

Class share

89%

of class CY24 spend

View profile →

Minoxidil

996K Part D claims (CY24) · 361K beneficiaries · First FDA approval: 1988-11-14

3 generic mfrs 2 plans require PA

Low NADAC$0.095

→

Avg plan cost$0.136

Part D spend $14.7M 1× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.